Funding

EVerZom Secures €10M to Advance Regenerative Medicine Therapies

Oct 15, 2025 | By Kailee Rainse

EverZom, a biotech startup from Strasbourg is developing exosome-based therapies to support tissue repair and regeneration. The company recently secures €10M funding to advance its R&D aiming to bring innovative treatments to patients and establish itself as a leader in the regenerative medicine field.

SUMMARY

EverZom, a biotech startup from Strasbourg is developing exosome-based therapies to support tissue repair and regeneration. The company recently secures €10M funding to advance its R&D aiming to bring innovative treatments to patients and establish itself as a leader in the regenerative medicine field.

The funding round was led by Capital Grand Est, the European Innovation Council (EIC) Fund, Sorbonne Venture by Audacia, and Aloe Private Equity, with participation from Paris Business Angels, the Capital Cell platform, and multiple family offices.

The company plans to use the funding to start its first clinical trial of EVerGel in 2026, explore new therapeutic applications of its exosomes in hepatology and dermatology, and further scale and industrialize its GMP-compliant exosome production platform.

RECOMMENDED FOR YOU

Funding

SpAItial Funding News- SpAItial Raises $13M Seed Funding For AI-native 3D Applications

Kailee Rainse

May 27, 2025

Funding

[Funding alert] London-based Fintech Company Ooodles Secures $12M in Funding

Team SR

Nov 9, 2023

Funding

[Funding alert] Polish Startup Envirly Raises €1.3 Million in Seed Funding

Team SR

Dec 1, 2023

Led by CEO Jeanne Volatron, EVerZom develops a proprietary bioproduction platform and therapies using mesenchymal stem cell-derived exosomes. Its approach combines exosomes with biomaterials to boost effectiveness.

The pipeline includes EVerGel (for Crohn’s complex perianal fistulas, entering clinical trials in 2026), Eviv (ACLF, preclinical), and exploratory projects in ophthalmology, regenerative medicine and non-pharma applications such as cosmetics and veterinary use.

"With this fundraising, EVerZom is reaching a decisive milestone. Our ambition is to bring the therapeutic potential of exosomes to patients suffering from diseases with high unmet medical need, where quality of life is severely impaired. Our priority is to achieve a first clinical proof-of-concept in Crohn’s perianal fistula and to establish the foundations of an industrial and partnership platform capable of driving the emergence of a new therapeutic class. We warmly thank our investors and partners for their trust and support," declared Jeanne Volatron, co-founder and CEO of EVerZom.

About EverZom

EverZom, founded in 2019 is a biotechnology company pioneering exosome-based therapies for tissue healing and organ regeneration. Its multi-patented platform enables sourcing, production, and formulation of exosomes for proprietary programs. Recognized by the European EIC Accelerator, EVerZom is positioned to lead innovation in regenerative medicine and oncology.